Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.39 |
| ▸ | HTR3B | O95264 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.39 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30091030 | 0.79 | BCHE (0.52) | BCHETSHRCHRM2CHRM4CHRM1 | |
| SCHEMBL26832198 | 0.76 | ABCB1 (0.45) | GAABCHETSHRABCB1 | |
| SCHEMBL28262599 | 0.73 | BCHE (0.55) | GAABCHEKMT2ACHRM2CHRM4 | |
| SCHEMBL26833384 | 0.73 | BCHE (0.42) | GAABCHETSHRABCB1 | |
| SCHEMBL8183692 | 0.72 | GAA (0.58) | GAABCHETSHRKMT2AABCB1 | |
| SCHEMBL26830869 | 0.72 | ABCB1 (0.48) | GAABCHEABCB1 | |
| SCHEMBL19320699 | 0.72 | BCHE (0.46) | GAABCHETSHRKMT2ACHRM2 | |
| SCHEMBL26290154 | 0.70 | ABCB1 (0.46) | GAABCHETSHRABCB1 | |
| SCHEMBL30629201 | 0.70 | BCHE (0.49) | GAABCHEKMT2ACHRM2CHRM4 | |
| SCHEMBL5487793 | 0.69 | ABCB1 (0.44) | BCHEABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429616-B2 | Synthesis and complete stereochemical assignment of psymberin/irciniastatin for use as antitumor compounds | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429616-B2 | Synthesis and complete stereochemical assignment of psymberin/irciniastatin for use as antitumor compounds | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2008-09-30 | — | — | US | disclosed |
| WO-2007011629-A2 | SYNTHESIS AND COMPLETE STEREOCHEMICAL ASSIGNMENT OF PSYMBERIN/IRCINIASTATIN FOR ANTI-TUMOR USE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2007-01-25 | — | — | WO | disclosed |
| US-20070015821-A1 | Synthesis and complete stereochemical assignment of psymberin/irciniastatin for use as antitumor compounds | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM | 2007-01-18 | — | — | US | disclosed |
| US-20070015821-A1 | Synthesis and complete stereochemical assignment of psymberin/irciniastatin for use as antitumor compounds | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015821-A1 | Synthesis and complete stereochemical assignment of psymberin/irciniastatin for use as antitumor compounds | HCCS, RPS24, RPS27 | GAA 2007/4885BCHE 902/4885TSHR 4205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.